Pancreatic Cancer Research

ResearcherAichi Medical UniversityNo recent work listed

Hiroyuki Sugimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0549-675X; OpenAlex author ID A5039896704. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2011: 4 papers · 2012: none · 2013: 3 papers · 2014: 4 papers · 2015: 3 papers · 2016: 5 papers · 2017: 3 papers · 2018: 1 paper

Papers 23

  1. Natural history of pancreatic cystic lesions: A multicenter prospective observational study for evaluating the risk of pancreatic cancer. Co-author DOI 10.1111/jgh.13967↗
  2. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2017.01.075↗
  3. The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.ijsu.2017.01.115↗
  4. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Co-author DOI 10.1016/j.surg.2017.04.023↗
  5. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. Co-author DOI 10.1002/jso.24147↗
  6. Lymph node ratio as parameter of regional lymph node involvement in pancreatic cancer. Co-author DOI 10.1007/s00423-016-1412-5↗
  7. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Co-author DOI 10.1097/md.0000000000003582↗
  8. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors … Co-author DOI 10.1097/md.0000000000004282↗
  9. The prognostic factors and trajectory of HRQOL in patients with pancreatic cancer who received psychiatric intervention. Co-author DOI 10.1111/jgh.13172↗
  10. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma w… Co-author DOI 10.1097/md.0000000000001647↗
  11. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000315↗
  12. Effectiveness of plasma treatment on pancreatic cancer cells. Co-author DOI 10.3892/ijo.2015.3149↗
  13. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Co-author DOI 10.1007/s00595-013-0752-9↗
  14. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0000000000000136↗
  15. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic h… Co-author DOI 10.1245/s10434-013-3329-3↗
  16. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Co-author PMID 25436375↗
  17. Value of peritoneal cytology in potentially resectable pancreatic cancer. Co-author DOI 10.1002/bjs.9307↗
  18. Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer. Co-author DOI 10.1016/j.surg.2013.05.004↗
  19. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Co-author DOI 10.1097/mpa.0b013e31827b2d7c↗
  20. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancr… Co-author DOI 10.1038/cgt.2010.65↗
  21. Pattern of lymph node metastasis spread in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182148342↗
  22. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Co-author DOI 10.1159/000324682↗
  23. Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Co-author DOI 10.1245/s10434-011-1604-8↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Kodera · 21 shared papers, 2011–2017 · strength 0.93
  2. Tsutomu Fujii · 21 shared papers, 2011–2017 · strength 0.93
  3. Suguru Yamada · 20 shared papers, 2011–2017 · strength 0.90
  4. Mitsuro Kanda · 17 shared papers, 2011–2017 · strength 0.76
  5. Akimasa Nakao · 9 shared papers, 2011–2015 · strength 0.31
  6. Norimitsu Yabusaki · 4 shared papers, 2016–2017 · strength 0.24
  7. Masaya Suenaga · 4 shared papers, 2014–2016 · strength 0.17
  8. Masamichi Hayashi · 4 shared papers, 2011–2017 · strength 0.17
  9. Hidemi Goto · 2 shared papers, 2016–2018 · strength 0.11
  10. Senju Hashimoto · 2 shared papers, 2016–2018 · strength 0.11
  11. Eizaburo Ohno · 2 shared papers, 2016–2018 · strength 0.11
  12. Yoshiki Hirooka · 2 shared papers, 2016–2018 · strength 0.11
  13. Shunji Nagai · 3 shared papers, 2011 · strength 0.07
  14. Akihiro Hirakawa · 1 shared paper, 2016 · strength 0.07
  15. Tomonari Asano · 1 shared paper, 2017 · strength 0.07
  16. Takuya Ishikawa · 1 shared paper, 2018 · strength 0.07
  17. Go Ninomiya · 1 shared paper, 2017 · strength 0.06
  18. Hideki Kasuya · 2 shared papers, 2011–2014 · strength 0.05
  19. Hiroki Kawashima · 1 shared paper, 2016 · strength 0.04
  20. Norifumi Hattori · 1 shared paper, 2015 · strength 0.04
  21. Kenneth K. Tanabe · 1 shared paper, 2013 · strength 0.03
  22. Bryan C. Fuchs · 1 shared paper, 2013 · strength 0.03
  23. Kazuo Yamamura · 1 shared paper, 2014 · strength 0.03
  24. Yukihiro Nishiyama · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.